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We are grateful to the investigators and institutions contributing data to the study (please, see appendix) and to Carmen Ruiz de Elvira and Virginie Chesnel for providing data management support from the EBMT registry. Therefore, annual vaccination is recommended for HSCT patients, their family, and the hospital staff caring for them (8) . Neuraminidase inhibitors have become widely used for therapy and higher doses and longer duration of antiviral treatment might be needed in transplant recipients (9) .
Authorship and Disclosures

ABSTRACT
The WHO recently declared the end of the A/H1N1 pandemic. However, the pandemic influenza A/H1N1 virus is still circulating and is included in the 2010/2011 trivalent vaccine.
Vaccine responses may be suboptimal after HSCT (10) (11) (12) including the responses to the 2009 A/H1N1 influenza vaccine (13) . In the summer of 2009, two separate surveys were designed to gather information on A/H1N1 infected HSCT patients to characterize the illness and determine risk factors for severe complications. LRT disease was defined as presence of pulmonary infiltrates and/or hypoxaemia. The assessment regarding the cause of death was made by the local investigator. Lymphopenia was defined as less than 0.3 x 10 9 /l and neutropenia as less than 0.5 x 10 9 /l. Data were collected in Stockholm for the EBMT and in Madrid for the GETH patients. All data were merged and analyzed in Stockholm. Proportions were compared using chi-square test.
DESIGN AND METHODS
Data
Univariate analysis was used to identify factors that led to LRT disease, ventilator use or death. Multivariate analysis was done with backwards stepwise logistic regression modelling using Statistica version 9.0.
RESULTS AND DISCUSSION
Two hundred and eighty-six patients were included in the study; 222 had undergone allogeneic and 64 autologous HSCT. and lymphopenia (p=0.002) were significant risk factors in the multivariate analysis.
Overall, 26 patients died during follow-up. Eighteen (6.3%) died from A/H1N1 infection or its complications; 11 of the 222 allogeneic transplant patients and seven of the 64 autologous transplant patients (p=NS). Sixteen patients died from respiratory failure while two patients died due to neurological disease. The median time from HSCT in the fatal cases was 13 months (0-184 months). Univariate risk factors for death were age, neutropenia, nosocomial acquisition, and lymphopenia. In the multivariate analysis, neutropenia (p<.01) and patient age (p=.04) were significant risk factors for death from A/H1N1 influenza.
Seven strains of 75 tested (9.3% of tested strains; 2.4% of the entire population) were shown to be oseltamivir-resistant. Six of these seven patients had LRT disease (p=0.005), five required mechanical ventilation (p<0.001), and five patients died, three of them from A/H1N1 infection or its complications (p<0.01).
Kumar et al has reported data on 237 SOT recipients with pandemic A/H1N1 infection (3).
Their results showed a high risk (31.7%) of pneumonia with 15.6% of recipients requiring admission to intensive care units. Our results in HSCT recipients were similar with 32.5% of patients developing pneumonia and 11.5% needing mechanical ventilation. The risk of death from A/H1N1 infection or its complications was, however, somewhat higher in our study than that reported by Kumar et al (6.3% vs. 4.2%). A small study from Australia showed a high mortality rate (21.9%) in hospitalized allogeneic HSCT patients and patients with malignancy (14) . Our corresponding proportion was 14.5%. Before the availability of neuraminidase inhibitors, mortality from influenza A in HSCT recipients was reported to be up to 15% (5, 7).
In more recent studies both morbidity and mortality have fallen, suggesting a positive effect of neuraminidase-inhibitor therapy (6, 15) . The rapid increase in the rate of oseltamivir resistance in non-pandemic H1N1 has, however, become a major concern (16).
The design for both the EBMT and the GETH studies probably identified the more severe cases, since patients with milder infections presumably did not seek medical attention as often as those with more significant symptoms. The denominator of A/H1N1-infected transplant recipients is therefore difficult to determine. It is, however, likely that the allogeneic HSCT recipients were more likely to be diagnosed and reported than those who had undergone autologous HSCT: we received five times as many reports for the former, despite the fact that similar numbers of allogeneic and autologous transplants are performed annually (17) . It is likely that the fact that we found no difference in outcome between the two cohorts represents a reporting bias. Many patients were diagnosed quite late after HSCT. This can have several causes including the general advice to these patients to contact their physicians when getting significant infections and that these patients are prone to more severe infections. In fact, the longest time from transplant to fatal A/H1N1 infection was 184 months after HSCT.
We found age and lymphopenia to be risk factors for pneumonia, mechanical ventilation and death. Studies show that the likelihood of severe complications from the pandemic increased with age presumably representing the presence of concomitant diseases. Similar results were found in the Kumar study (3) . Two small studies of children with malignancies infected with the A/H1N1 pandemic strain also suggest relatively mild disease (18, 19) . Lymphopenia has been identified as a risk factor for LRT disease, both for influenza and for infections with other respiratory viruses (5). Although we found that neutropenia was a significant risk factor for death, it was not for pneumonia or for mechanical ventilation. This could be due to an increased risk for secondary bacterial infections. Among allogeneic patients, a transplant from an unrelated or mismatched family donor was at risk factor for LRT disease. This is Oseltamivir therapy initiated within 48 hours of symptom onset was associated with reduced risk for pneumonia (3, 4) and need for intensive care (3). While most patients received antiviral therapy, we have no information about time to initiation. It is logical; however, that rapid antiviral treatment is at least as important after HSCT as after organ transplantation, despite the absence of formal, prospective, controlled studies. Although the rates of oseltamivir resistance have until now been quite low for the pandemic A/H1N1 strain (20) , it is noteworthy that we found a relatively high incidence and this also seemed to affect the severity of the disease in these patients. However, it is likely that severe disease prompted testing for resistance. Thus, our finding does not necessarily imply that oseltamivir resistant pandemic A/H1N1 strains are more pathogenic. There is another report of a high incidence of oseltamivir resistance in haematology/oncology patients (21) suggesting that immunosuppressed patients are more at risk of having resistant strains.
Vaccination is the key preventive measure against influenza and is recommended both by health authorities and by scientific organizations (8, 22) . Experience from the A/H1N1 pandemic, however, shows the difficulty of rapidly producing and delivering a pandemic strain vaccine. An important issue is, therefore, whether the seasonal vaccine had any effect.
Unfortunately, we found no protective effect in the multivariate analysis from either the seasonal or the A/H1N1 vaccines against the more severe complications. The possibility of a protective effect of the seasonal vaccine has been suggested by an early study from Mexico (23) and findings of cross-reacting antibodies in some but not all studies (24) . It should be noted that most patients receiving A/H1N1 vaccine only received a single vaccination and the interval between vaccination and infection was short (data not shown) therefore no conclusions regarding efficacy can be drawn.
Our study shows that new influenza A strains can cause significant morbidity and even mortality in HSCT recipients and its impact would have been devastating had the strain been more pathogenic. Strategies must therefore be in place as early as possible during the early phase of influenza pandemics and large outbreaks of seasonal influenza for management of high risk individuals. 
